Introduction
Antibody oligonucleotide conjugates (AOCs) represent an emerging class of biotherapeutics that combine the cell-targeting precision of antibodies with the gene-modulating capabilities of oligonucleotides. Structurally, AOCs consist of a monoclonal antibody (or antibody fragment) covalently linked to an oligonucleotide, such as small interfering RNA (siRNA), antisense oligonucleotide (ASO), or splice-switching oligonucleotide (SSO). The antibody component serves as a targeting vehicle, binding to specific cell-surface antigens to facilitate receptor-mediated internalization, while the oligonucleotide payload exerts its function in the cytoplasm or nucleus to modulate gene expression. This dual mechanism enables AOCs to address one of the long-standing challenges in oligonucleotide therapy: selective and efficient delivery to target tissues beyond the liver. The therapeutic importance of AOCs lies in their potential to expand the reach of oligonucleotide-based therapies to new disease areas and cell types. Traditional oligonucleotide drugs, while successful in treating certain liver and muscle diseases, are limited by poor cellular uptake and nonspecific distribution. By leveraging antibody-mediated endocytosis and Fc receptor recycling pathways, AOCs can achieve targeted intracellular delivery, reduce systemic toxicity, and improve therapeutic index. This approach opens the door to treating diseases where delivery barriers have historically impeded nucleic acid therapeutics, particularly in tissues such as skeletal muscle, heart, and central nervous system. AOCs are being developed for a growing range of disease indications, spanning genetic, neuromuscular, and oncologic disorders. In genetic diseases, AOCs have shown promise in targeting messenger RNA transcripts responsible for conditions such as myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD). For instance, AOCs directed to transferrin receptor 1 (TfR1) on muscle cells can deliver splice-modifying oligonucleotides that restore functional dystrophin expression in DMD models. In oncology, antibody-siRNA conjugates are being investigated for selective silencing of oncogenes or drug-resistance mediators in tumor cells expressing specific surface antigens, such as HER2 or EGFR. Additionally, emerging research suggests that AOCs could be tailored for inflammatory and metabolic diseases by modulating key genetic regulators within specific cell populations. Overall, AOCs represent a powerful therapeutic platform that bridges the precision of biologics with the versatility of genetic medicine.Current Strategies for Therapeutic Oligonucleotide Delivery
Current strategies for oligonucleotide delivery include direct chemical conjugates such as GalNAc for hepatocyte targeting, lipid-based nanoparticles (LNPs) for systemic delivery, viral or vesicle-based systems for efficient cellular entry, polymeric and peptide-based nanoparticles for tunable uptake, and localized physical delivery methods such as intrathecal or intravitreal injection. Collectively, these platforms aim to overcome biological barriers, protecting oligonucleotides from degradation, improving biodistribution, and ensuring efficient cellular internalization and release. While conjugate systems like GalNAc and LNPs have achieved clinical success, particularly for liver delivery, expanding effective and safe delivery to extrahepatic tissues remains challenging. Overall, the main disadvantages of current approaches include limited tissue specificity beyond the liver, poor endosomal escape efficiency, immunogenicity or toxicity concerns, and complex manufacturing requirements that hinder broad clinical translation.Advantages and Disadvantages of AOCs
AOCs bring together several appealing features- Specific cell/tissue targeting: By using an antibody that binds a cell‐surface antigen (e.g., a receptor highly expressed in a target tissue), AOCs can achieve selective delivery of the oligonucleotide payload to that tissue, improving biodistribution and reducing systemic exposure. For example, an AOC targeting the transferrin receptor (TfR1) directed to skeletal and cardiac muscle achieved much higher payload delivery versus naked oligonucleotide.
- Gene‑level modulation: The oligonucleotide payload allows modulation of the transcriptome (silencing, splicing correction, degradation) rather than just delivering a cytotoxin. This means potential to treat diseases caused by genetic mutations, aberrant splice variants, or over‑expressed transcripts.
- Extending reach beyond liver/other easy tissues: Many oligonucleotide therapies (siRNA, ASO) preferentially go to the liver or kidney or are constrained by delivery challenges. AOCs can enable delivery to less accessible tissues (e.g., muscle, heart, CNS) by virtue of the antibody‐mediated targeting and internalization. For example, the study on mice/monkeys showed >15‑fold higher delivery to muscle tissue via TfR1‑targeted AOCs.
- Potential for reduced systemic toxicity and improved therapeutic windows: Because the delivery is more targeted, less of the oligonucleotide may go to off‐target tissues; plus the antibody can bring favorable pharmacokinetics (longer half‑life, defined distribution) that small oligos often lack.
| Delivery Approach | Key Advantages | Key Disadvantages |
| GalNAc Conjugates | – Highly efficient and specific uptake by hepatocytes – Simple, chemically defined composition – Proven clinical success – Enables infrequent subcutaneous dosing | – Restricted to liver targeting – Limited extrahepatic delivery – Endosomal escape remains suboptimal |
| Lipid Nanoparticles (LNPs) | – Effective systemic delivery – Protects oligonucleotides from degradation – Adjustable formulation for biodistribution and release – Clinically validated | – Predominant accumulation in liver/spleen – Potential immune activation or infusion reactions – Complex manufacturing and cold-chain requirements |
| Polymeric / CPP / Inorganic Nanoparticles | – Highly tunable structure and surface chemistry – Broad range of materials for controlled release and stability – Potential for targeting via chemical modification | – Toxicity of cationic polymers – Poor reproducibility and scalability – Limited clinical translation due to safety and efficiency concerns |
| Viral / Vesicle-based Systems (AAV, VLPs, EVs) | – High efficiency of cellular entry – Potential for durable intracellular delivery – Natural or engineered tropism for specific tissues | – Immunogenicity and biosafety issues – Complex and costly manufacturing – Regulatory and batch variability challenges |
| Physical / Local Delivery (Intrathecal, Intravitreal, Electroporation) | – Direct access to target tissues (CNS, eye, muscle) – High local concentration, minimal systemic exposure | – Invasive administration – Limited to accessible tissues – Inefficient for systemic or repeated dosing |
| Antibody–Oligonucleotide Conjugates (AOCs) | – Precise cell and tissue targeting using antibody specificity – Potential to deliver oligonucleotides beyond liver (e.g., muscle, tumor) – Compatible with established antibody platforms and FcRn recycling for long half-life | – Complex conjugation chemistry and optimization (linker, payload ratio) – Large molecular size limits tissue penetration – Endosomal escape inefficiency |
| Antibody Target | Tissue / Cell Type Targeted | Representative Genetic Disease Indications | Rationale for Use in AOCs |
| Transferrin Receptor 1 (TfR1 / CD71) | Skeletal and cardiac muscle, neurons | Duchenne muscular dystrophy (DMD), Myotonic dystrophy type 1 (DM1), Amyotrophic lateral sclerosis (ALS), Spinal muscular atrophy (SMA) | High expression in muscle and neuronal cells; enables efficient receptor-mediated uptake and cytoplasmic release of oligonucleotide payloads. |
| Insulin-like Growth Factor 2 Receptor (IGF2R / CI-M6PR) | Skeletal muscle, heart, liver | Pompe disease | Mediates uptake into lysosome-rich tissues; leverages natural mannose-6-phosphate pathway for intracellular delivery in glycogen storage disorders. |
| Asialoglycoprotein Receptor 1 (ASGR1) | Hepatocytes (liver) | Familial hypercholesterolemia, alpha-1 antitrypsin deficiency, Wilson disease | Liver-specific receptor for hepatocyte-targeted oligonucleotide delivery in metabolic and genetic liver disorders. |
| Transferrin Receptor 2 (TfR2) | Liver, erythroid precursors | Beta-thalassemia, hereditary hemochromatosis | Provides selective uptake in liver and erythroid cells; alternative route for systemic oligonucleotide delivery targeting hematologic and hepatic genes. |
| Low-density Lipoprotein Receptor-Related Protein 1 (LRP1) | Brain endothelial cells, neurons | Huntington’s disease, Friedreich’s ataxia, other neurodegenerative disorders | Enables blood–brain barrier transcytosis and neuronal uptake for CNS-targeted oligonucleotide therapy. |
| Neural Cell Adhesion Molecule (NCAM / CD56) | Neurons, muscle cells | Spinal muscular atrophy (SMA), congenital myopathies | Surface receptor on neural and muscle cells that supports receptor-mediated endocytosis and neuron-specific targeting. |
| Insulin Receptor (INSR) | Endothelium, neurons, muscle | Lysosomal storage disorders, neurogenetic diseases | Exploited for transcytosis across the blood–brain barrier and uptake into metabolic tissues. |
| CD36 (Scavenger receptor) | Muscle, adipose, endothelial cells | Mitochondrial fatty acid oxidation disorders | Supports uptake into oxidative tissues; potential target for metabolic myopathies. |
| LRP8 (ApoER2) | Brain, neurons | Rett syndrome, Fragile X syndrome | Brain-expressed receptor that mediates endocytosis and synaptic delivery, enabling oligonucleotide entry into neurons. |
AOC Cell Surface Targets for Genetic Disease
AOCs are engineered to exploit cell type-specific surface receptors that mediate efficient internalization, enabling targeted delivery of therapeutic oligonucleotides for genetic diseases. In muscle, transferrin receptor 1 (TfR1), insulin-like growth factor 2 receptor (IGF2R), and CD98 heavy chain (CD98hc) are leading targets due to their high expression on myocytes and their capacity to undergo receptor-mediated endocytosis, facilitating uptake of conjugated cargo. In the liver, asialoglycoprotein receptor 1 (ASGR1) and transferrin receptor 2 (TfR2) provide selective entry points into hepatocytes, leveraging well-characterized clathrin-mediated internalization pathways. For central nervous system (CNS) delivery, low-density lipoprotein receptor–related proteins (LRP1 and LRP8), insulin receptor (INSR), and neural cell adhesion molecule (NCAM) are under investigation for their ability to cross the blood–brain barrier (BBB) and mediate neuronal uptake. Despite differences in tissue localization, these receptors share common mechanisms involving ligand binding, endosomal trafficking, and subsequent release of the oligonucleotide cargo into the cytoplasm after endosomal escape, processes essential for productive gene modulation in targeted cells.AOC Oligonucleotide Mechanisms of Gene Regulation
Oligonucleotides can modulate gene expression through diverse mechanisms, including mRNA degradation, splicing modulation, transcription inhibition, or translation blockade. Selection of the oligonucleotide type depends on the therapeutic goal, the disease-causing gene, and the required intracellular target (nuclear or cytoplasmic). Examples of mechanistically distinct oligonucleotides for treating genetic diseases: Antisense Oligonucleotides (ASOs) ASOs are single-stranded nucleic acids that bind complementary RNA sequences to regulate gene expression. Depending on chemical design, they can promote RNase H–mediated degradation of the target RNA or sterically block RNA processing events such as translation initiation or RNA maturation. The result is reduced production or altered processing of the target transcript siRNA (small interfering RNA) siRNAs are double-stranded oligonucleotides that enter the RNA interference (RNAi) pathway. The antisense strand is loaded into the RNA-induced silencing complex (RISC), which then recognizes and endonucleolytically cleaves complementary mRNA. This cleavage leads to rapid mRNA degradation and potent gene silencing. Splice-switching Oligonucleotides (SSOs) SSOs are designed to bind pre-mRNA at specific splice junctions or regulatory elements. They act through steric hindrance, blocking spliceosome components or regulatory proteins from binding. This forces the spliceosome to include or skip targeted exons, thereby altering the final mRNA isoform and restoring or modifying protein expression. Antigene Oligonucleotides (AGOs) AGOs bind directly to double-stranded genomic DNA or form triplex structures at promoter regions. By competing with transcription factors or altering chromatin accessibility, they inhibit transcription initiation or modulate the epigenetic state of the locus. This mechanism regulates gene expression at the DNA level before RNA is produced. Phosphorodiamidate Morpholino Oligomer (PMO) A synthetic, chemically modified oligonucleotide widely used for treating genetic diseases, especially those involving errors in mRNA splicing. Bind to pre-mRNA and physically block splice sites or regulatory sequences. This can restore or alter mRNA splicing, enabling production of a functional or partially functional protein. Together, these oligonucleotide modalities provide complementary strategies for correcting or compensating for genetic defects. ASOs and siRNAs enable precise suppression of harmful gene products, while SSOs can restore functional protein expression by repairing defective splicing patterns. AGOs extend intervention to the DNA level, offering the potential to modulate gene transcription upstream of RNA production. Collectively, they form a versatile therapeutic toolkit that can target diverse molecular consequences of genetic disease, enabling tailored interventions based on the specific nature of each mutation.Genetic Defects Under Investigation for AOC Therapy
Examples of genetic defects under investigation for AOC therapy. Myotonic Dystrophy Type 1 (DM1)- Genetic defect: Expansion of a CTG repeat in the 3′ UTR of the DMPK gene, leading to toxic RNA that sequesters MBNL proteins and causes spliceopathy.
- Pathology: Multisystem neuromuscular disease: myotonia, muscle weakness, cardiac conduction defects, respiratory compromise, cognitive/behavioral issues.
- AOC under development: AOC 1001 (delpacibart etedesiran) – an antibody oligonucleotide conjugate delivering siRNA against DMPK mRNA.
- Genetic defect: Aberrant expression of DUX4 gene (often due to contraction of D4Z4 repeats + permissive haplotype) in skeletal muscle, leading to toxicity.
- Pathology: Progressive weakness of facial, shoulder girdle and upper arm muscles, variable severity, disability over time.
- AOC under development: AOC 1020, a TfR1-targeting monoclonal antibody engineered for muscle delivery conjugated via a non-cleavable linker to siRNA to trigger RISC-mediated degradation of DUX4 mRNA in skeletal muscle
- Genetic defect: Mutation in the PLN gene (autosomal dominant) induces toxic phospholamban aggregates leading to cardiomyocyte death, arrhythmia, and dilated cardiomyopathy.
- Pathology: Heart disease: dilation, arrhythmias (including sudden cardiac arrest risk), heart failure progression.
- Example AOC under development: AOC 1086, an AOC designed to deliver siRNA to knock down PLN mRNA in cardiomyocytes.
- Genetic defect: Mutations in PRKAG2 gene (autosomal dominant) lead to constitutive AMPK activity resulting in excessive cardiac glycogen, hypertrophy, conduction disease, arrhythmias.
- Pathology: Cardiomyopathy with hypertrophy, arrhythmias (e.g., Wolff-Parkinson-White), conduction block, heart failure risk.
- Example AOC under development: AOC 1072, an AOC designed to deliver siRNA targeting PRKAG2 mRNA in heart tissue.
Conclusion
Antibody-oligonucleotide conjugates (AOCs) represent a rapidly advancing modality that offers the potential to overcome many limitations of traditional oligonucleotide delivery systems. By leveraging antibody-mediated targeting, AOCs improve tissue specificity, expand the range of deliverable oligonucleotide chemistries, and reduce systemic exposure—advantages that collectively enhance therapeutic precision for genetic diseases. Nonetheless, challenges remain, including the need to optimize receptor selection, improve endosomal escape, and establish scalable, reproducible manufacturing processes. Across diverse genetic defects, receptor selection has emerged as a central design parameter, dictating the efficiency and selectivity of oligonucleotide delivery to disease-relevant tissues. Parallel progress in oligonucleotide engineering—from splice-modifying antisense oligos to RNA interference and upregulation strategies—has broadened the mechanistic toolkit available for AOCs, enabling therapeutic approaches tailored to distinct pathogenic mechanisms. As a result, a growing set of monogenic disorders with unmet medical need are now under active investigation for AOC-based intervention. Together, these developments highlight the transformative potential of AOCs as a next-generation platform for genetic disease therapy. Continued refinement of targeting antibodies, oligonucleotide mechanisms, and disease-specific delivery strategies will be essential to realizing the full clinical impact of this technology and advancing a new class of precision genetic medicines. Disclaimer: This blog post is intended solely for educational and scientific informational purposes. Any mention of therapeutic drug names, including FDA-approved medications, is for the purpose of accurate reporting and discussion of biomedical research and does not constitute medical advice, endorsement, or promotion. Readers should not interpret the content as a recommendation for any specific treatment. Always consult a qualified healthcare professional for medical advice or treatment decisions.About Marin Biologic Laboratories
Our Recent Publication/Meeting Presentation on Gene Therapy
1. Development of VNX-101, an Adeno-Associated Virus with Less Immunogenicity and Efficient Long-Term Expression of a CD19 T-Cell Engager. Molecular Therapy Methods & Clinical Development, published online July 24, 2025.
3. 2Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. Journal of Immunological Methods. 2025. 545-114004.
3. Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
4. American Society of Hematology (ASH) Annual Meeting 2024. Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.
Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise
With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline. Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.Download the full presentation: Development of Custom Cell Based and In vitro Potency and Pharmacokinetics (PK) Assays for AAV vectors- Marin biologic Laboratories
Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)
Drug Discovery & Development Assays Offered by Marin Biologic Laboratories (MarinBio)
- ADME/Tox
- Molecular Biology
- The Art of Cell Culture
- Exosomes
- Stability Services
- Potency Assay
- Gene Therapy Assays
- Immunotherapy Assays
- Antiviral Therapy Assays
- cGMP
- MLR
- Cell Based Assays
- ELISA
- Flow Cytometry
- Protein
- PCR-qPCR
- Immunoassay
- Radioimmunoassay
- GLP
- Transfection
- Cell Therapy Assays
- Targeted Protein Degradation
- Research to Commercialization
